Premium
Efficacy and Safety of Hemoglobin‐Polyethylene Glycol Conjugate (Pyridoxalated Polyethylene Glycol Hemoglobin) as an Oxygen‐Carrying Resuscitation Fluid
Author(s) -
Iwasaki Keiji,
Iwashita Yuji,
Ikeda Kenro,
Uematsu Toshio
Publication year - 1986
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.1986.tb02606.x
Subject(s) - hemoglobin , blood substitute , polyethylene glycol , peg ratio , exchange transfusion , resuscitation , medicine , transaminase , blood urea nitrogen , chemistry , pharmacology , anesthesia , biochemistry , creatinine , finance , economics , enzyme
The safety and efficacy of a conjugate of pyridoxalated hemoglobin and polyethylene glycol (pyridoxalated PEG hemoglobin) were evaluated after administration to rats. The LD 50 (lethal dose for 50% survival of group) of pyridoxalated polyethylene glycol (PEG) hemoglobin was >200 ml/kg. Any pro‐or anticoagulation activity was not demonstrated in in vitro coagulation tests. One day after 70% exchange‐transfusion with pyridoxalated PEG hemoglobin, slight elevations of the serum glutamic‐oxaloacetic transaminase, serum glutamie‐pyruvic transaminase, and blood urea nitrogen values, which were 101.7 ± 22.6 IU/L, 33.3 ± 7.2 IU/L, and 23.1 ± 1.4 mg/dl, respectively, were observed. However, these values were in the normal range after 3 days. With >90% exchange‐transfusion, all rats exchange‐transfused with pyridoxalated PEG hemoglobin survived for >2 weeks in contrast to the death of all the rats exchangetransfused with stroma‐free hemoglobin or albumin.